Sacituzumab Govitecan in Patients With Solid Tumor

  • End date
    Dec 24, 2025
  • participants needed
  • sponsor
    Everest Medicines
Updated on 24 November 2021


The purpose of this study is to evaluate the efficacy of sacituzumab govitecan in patients with unresectable, locally advanced or metastatic solid tumor

Condition Solid Tumor, Solid Tumour, Solid Tumors, Solid Neoplasm
Treatment Sacituzumab Govitecan-hziy
Clinical Study IdentifierNCT05119907
SponsorEverest Medicines
Last Modified on24 November 2021


Yes No Not Sure

Inclusion Criteria

Male or female adult, 18 years of age or older providing written informed consent
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Histologically or cytologically-documented, incurable locally advanced or metastatic solid tumor of one of the following types
Cohort A: oesophageal squamous-cell carcinoma that was refractory or intolerant to fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy
Cohort B: gastric adenocarcinoma that was refractory or intolerant to fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy
Cohort C: cervical cancer that was refractory or intolerant to platinum-based and taxane-based chemotherapy
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) in accordance with RECIST v 1.1, bone-only disease is not measurable and is not permitted
Availability of archival tumor tissue or newly acquired biopsy (unstaining tumor slides, recommended from metastasis sites)
Adequate bone marrow, hepatic and renal function
Recovered from all prior treatment-related toxicities to Grade 1 or less by NCI-CTCAE v 5.0 (except alopecia or peripheral neuropathy that may be Grade 2 or less)
Patients must have completed all prior cancer treatments at least 2 weeks prior to the first dose including chemotherapy , radiotherapy and major surgery. Prior antibody treatment for cancer must have been completed at least 3 weeks prior to the first dose
Patients must have at least a 3-month life expectancy

Exclusion Criteria

Previous treatment with topoisomerase I inhibitors as a free form or as other formulations
Previous treatment with Trop-2 targeted therapy
Patients with a history of or current central nervous system (CNS) metastases. A scan to confirm the absence of brain metastases is not required. Patients with unknown CNS metastatic status and any clinical signs indicative of CNS metastases are eligible if CNS metastases are excluded using CT and/or MRI scans
Known additional malignancy within 3 years prior to enrollment with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or curatively resected in situ cancers
Patients known to be human immunodeficiency virus positive
Patients with active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Hepatitis B core antibody (HBcAb) testing is required and if positive, then HBV DNA testing will be performed and if positive the patient will be excluded
Known history of unstable angina, myocardial infarction (MI), or chronic heart failure present within 6 months of first dose or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy or left ventricular ejection fraction < 50%
Known history of clinically significant active chronic obstructive pulmonary disease, or other moderate-to-severe chronic respiratory illness present within 6 months of the first dose
Patients with active chronic inflammatory bowel disease (ulcerative colitis
Crohn disease) and patients with a history of bowel obstruction or
gastrointestinal (GI) perforation
Infection requiring systematic antibiotic use within 1 week of the first dose
High dose systemic corticosteroids within 2 weeks prior to the first dose (however, low dose corticosteroids 10 mg prednisone or equivalent daily are permitted provided the dose is stable for 4 weeks)
Patients who have received a live vaccine within 30 days of first dose
Rapid deterioration during Screening prior to the first dose, eg, significant change in PS, substantial increase in hydrothorax, unstable pain symptoms requiring modifications in analgesic management
Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations
Women who are pregnant or lactating
Women of childbearing potential or fertile men unwilling to use highly effective contraception during study and up to 6 months after treatment discontinuation in women of childbearing potential and 3 months in males post last investigational product (IP) administration
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note